| Jul 15 |
Scinai stock soars 54% on preclinical study for psoriasis drug
|
| Jul 15 |
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model
|
| Jul 8 |
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity
|
| Jul 3 |
Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
|
| Jul 3 |
Scinai Immunotherapeutics GAAP EPS of $0.00
|
| Jul 2 |
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
|
| Jun 18 |
Why Chegg Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
|
| Jun 13 |
Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.
|
| Jun 7 |
Scinai Immunotherapeutics regains Nasdaq compliance
|
| Jun 7 |
Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement
|
